Industry Pulse

Library

Newly Discovered Peptide in Cardiovascular Field: A "New Weapon" for Blood Pressure Reduction and Cardioprotection—Alamandine-(1-5)

Peptide Molecules "Breaking Symmetry" Enable Ultralow-Voltage Ferroelectric Materials and Promote Neuronal Growth

Controlled Cyclization Meets Ribosomal Synthesis: The Birth of a New-Generation Bicyclic Peptide Platform

Breaking the Bottleneck of Cysteine Selective Modification: Triazine-Pyridine Chemistry Enables Precision Protein Coupling

When Antifungal Drugs Fail, Do We Have a Backup Plan? Antimicrobial Peptides Emerge as New Hope Against "Superfungi"

Additive-Free Peptide Synthesis Using Pentafluorophenyl Esters as the Sequence Oligopeptide Synthesis via a Flow Reaction

Discovery of antimicrobial peptides in the global microbiome with machine learning

Hydrophobic Tag-Assisted Liquid-Phase Synthesis of Tirzepatide

Breakthrough Advancement! Novel Hemostatic Gel Offers New Solution for Duodenal Diverticular Hemorrhage

“A Broad-Spectrum Lasso Peptide Antibiotic Targeting the Bacterial Ribosome ”

0102

Selecting the Right Peptide Synthesizer: Market Insights and Dilunbio’s Comprehensive Solution

2025-08-28

1. The Growing Peptide Synthesis Market: Why It Matters

The global peptide synthesis industry is expanding rapidly, driven by the rise of peptide-based therapeutics, vaccines, and biologics.

Grand View Research projects the peptide synthesis market will grow from USD 961.5 million in 2024 to USD 1.84 billion by 2033, with a CAGR of 7.71% .
MarketsandMarkets reports growth from USD 0.81 billion in 2024 to USD 1.41 billion by 2029, at a faster CAGR of 11.7% (MarketsandMarkets).
Precedence Research predicts the market will reach USD 1.347 billion by 2034, almost doubling from USD 678.1 million in 2025, with a CAGR of 7.93% (Precedence Research).

👉 These consistent growth figures highlight both the increasing demand for peptide synthesizers and the importance of choosing a platform that balances scale, flexibility, and compliance.

2. Key Selection Criteria

When selecting a peptide synthesizer, consider:

Scale & Throughput: From mg-scale academic use, to mmol-scale pilot production, up to mol-scale industrial synthesis.
Process Flexibility: Ability to perform asynchronous synthesis, incorporate non-standard amino acids, and optimize coupling/deprotection methods individually.
Automation & Intelligence: Remote monitoring, automated data logging, and customizable workflows.
Regulatory Compliance: Conformance with FDA 21 CFR Part 11 standards (audit trails, electronic signatures, immutable records).
Cost Efficiency & Support: Investment vs. consumables cost, solvent recycling, compatibility, and after-sales service.

3. Dilunbio’s Comprehensive Solution

Founded in 2012, Beijing Dilun Biotechnology Co., Ltd. (Dilunbio) has developed a complete product line spanning research, pilot, production, and industrial peptide synthesis.

(a) Full Product Line Coverage

Research-grade: 319 Pro™, 286 Pro™, 386 Pro™, 386 MW™.
Pilot-scale: 286 Max™, 486 Pro™.
Industrial production: 586 Pro™, 686 Series™.
High-throughput: Tetras™ – capable of running up to 106 independent reaction vessels, enabling asynchronous peptide library synthesis.

(b) Asynchronous Multi-Channel Advantage

Unlike synchronous international platforms, Dilunbio supports:

Independent addition/removal of resin per channel.
Individual coupling and deprotection conditions.
Multi-user parallel operation.

This flexibility is crucial for R&D workflows, where optimization and impurity profiling demand different parameters across channels.

(c) Intelligent Remote Control & Compliance

Remote access: real-time monitoring and operation outside the lab.
Full compliance: complete audit trails, electronic signatures, secure backups, all FDA 21 CFR Part 11-compliant.

(d) Efficiency & Sustainability

Microwave acceleration (386 MW™): Reaction time reduced to 1/10–1/30 of conventional methods, with higher yields.
Solvent recycling (586 Pro™): Achieves up to 40% reduction in solvent use, lowering costs and environmental burden.

(e) Local Service, Global Standards

Widely adopted by leading universities (Tsinghua, Peking University) and pharma companies (Hengrui, Hansoh, Yangtze River Pharma).
Exported to the US, Germany, Japan, Australia, and more.
Combines fast domestic after-sales response with international regulatory alignment.

4. Recommendations by User Need

User Type	Recommended Dilunbio Systems	Why It Fits
Academic researchers	319 Pro™, 286 Pro™, 386 Pro™	Flexibility in method optimization, asynchronous multi-channel.
Drug discovery teams	386 MW™, Tetras™	High throughput libraries, microwave acceleration.
Pilot-scale R&D	286 Max™, 486 Pro™	Stable scale-up, interchangeable reactors.
Industrial manufacturing	586 Pro™, 686 Series™	Large-scale GMP-compliant production.

5. Conclusion

With the peptide synthesis market projected to grow at 7–12% annually worldwide (Grand View Research; MarketsandMarkets; Precedence Research), laboratories and enterprises must invest in future-proof, flexible, and compliant equipment.

Dilunbio stands out with:

A full-spectrum product portfolio (research to industrial).
Asynchronous multi-channel synthesis for unmatched flexibility.
High-throughput capabilities (up to 106 independent reactors).
21 CFR Part 11 compliance with intelligent remote control.
Proven domestic adoption and international exports.

For researchers, pharma innovators, and manufacturing enterprises seeking comprehensive, efficient, and regulatory-compliant peptide synthesis solutions, Dilunbio is a strategic partner you can trust.